Abstracts tagged "Chemokine Receptors"

Abstract Number: 007 • 2020 Pediatric Rheumatology Symposium
Dense Genotyping of Immunologic Loci Identifies CXCR4 as a Novel Susceptibility Locus for Systemic Juvenile Idiopathic Arthritis
Emily Shuldiner ¹, Elaine Remmers ², Miranda Marion ³, Marc Sudman ⁴, Colleen Satorius ⁵, International Childhood Arthritis Genetics Consortium (INCHARGE), Juvenile Arthritis Consortium for the Immunochip (JACI), Wendy Thomson ⁶, Michael Ombrello¹, Patricia Woo ⁷, Carl Langefeld ⁸, Sampath Prahalad ⁹ and Susan Thompson ¹⁰, ¹NIAMS, NIH, Bethesda, ²National Human Genome Research Institute, Bethesda, ³Wake Forest University, Winston-Salem, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, ⁵NHGRI, NIH, Bethesda, ⁶Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁷London, United Kingdom, ⁸Winston Salem, ⁹Emory + Children's Pediatric Institute, Atlanta, ¹⁰Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Cincinnati
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a severe, potentially lethal inflammatory condition. It accounts for a disproportionate share of morbidity and mortality among childhood…
Abstract Number: 17 • 2019 ACR/ARP Annual Meeting
Transcription Factor Fli-1 Impacts Lupus Nephritis by Orchestrating CXCL10/CXCR3 Axis
Xuan Wang¹, Mara Lennard Richard ¹, Tomika Caldwell ², Brittany Henry ², Tammy Nowling ², Jim Oates ³, Gary Gilkeson ⁴ and Xian Zhang ¹, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Division of Rheumatology & Immunology/Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC
Background/Purpose: Lupus nephritis is a major cause of death in both animal models and human patients. Expression of Fli-1, a member of the Ets family…
Abstract Number: 21 • 2019 ACR/ARP Annual Meeting
Immuno-Phenotypic Analysis of Peripheral Blood Mononuclear Cells in Rheumatoid Arthritis Patients Treated with E6011, a Humanized Anti-Fractalkine Monoclonal Antibody
Tomohiro Yamada¹, Jungo Kakuta ¹, Eri Fusaoka-Nishioka ¹, Jun-ichi Ito ², Nobuyuki Yasuda ³, Tetsu Kawano ³ and Toshio Imai ³, ¹KAN Research Institute Inc., Kobe, Japan, ²EISAI Co. Ltd., Tsukuba, Japan, ³KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: Fractalkine (FKN) and its solo receptor CX3CR1 are deeply involved in the pathogenesis of rheumatoid arthritis (RA). FKN is expressed on vascular endothelium, while…
Abstract Number: 103 • 2018 ACR/ARHP Annual Meeting
Identification of IL-17+ and IL-10+ TCRαβ+ CD4- CD8- double Negative (DN) T Cell Subsets in Lupus-Prone Mice and Patients with SLE and Their Significance in Predicting Renal Involvement
Yi Li¹, Hao Li², Vasileios C. Kyttaris³ and George C Tsokos⁴, ¹Medicine, BIDMC, Boston, MA, ²Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA, ⁴Division of Rheumatology, Department of Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA
Background/Purpose: We have previously shown that DN T cells are expanded in both lupus-prone mice and patients with SLE and we have demonstrated that this…
Abstract Number: 984 • 2018 ACR/ARHP Annual Meeting
Reduced Expression of CX3CR1 in Peripheral CD14++CD16+monocytes Is a Novel Feature of Patients with Systemic Lupus Erythematosus
Keiko Yoshimoto¹, Katsuya Suzuki¹, Shuntaro Saito², Jun Kikuchi¹ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Fractalkine (FKN, CX3CL1) and its receptor, CX3CR1, play an important role in chemotaxis of immune cells, such as cell adhesion, migration and infiltration into…
Abstract Number: 995 • 2018 ACR/ARHP Annual Meeting
Anti-Fractalkine Monoclonal Antibody Inhibits Joint Destruction through Suppression of Osteoclast Precursor Migration and Induces Synovial Cell Death in Collagen-Induced Arthritis Model Mice
Kana Hoshino-Negishi¹, Masayoshi Ohkuro², Tomoya Nakatani¹, Wataru Ikeda¹, Yoshikazu Kuboi¹, Naoto Ishii¹, Nobuyuki Yasuda¹ and Toshio Imai³, ¹KAN Research Institute, Inc., Kobe, Japan, ²Research Project Promotion Group, EA Pharma Co., Ltd., Kawasaki, Japan, ³President & CEO, Chief Scientific Officer, KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately…
Abstract Number: 1001 • 2018 ACR/ARHP Annual Meeting
Anti-Fractalkine Monoclonal Antibody Dislodges Intravascular Monocytes Involved in Exacerbation of Synovial Inflammation in Collagen-Induced Arthritis Model
Wataru Ikeda¹, Kana Hoshino-Negishi¹, Eri Fusaoka-Nishioka¹, Tomoya Nakatani¹, Yoshikazu Kuboi¹, Naoto Ishii¹, Nobuyuki Yasuda¹ and Toshio Imai², ¹KAN Research Institute, Inc., Kobe, Japan, ²President & CEO, Chief Scientific Officer, KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately…
Abstract Number: 1023 • 2018 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells That Infiltrate the Lungs Produce Profibrotic Cytokines and Chemokines in Bleomycin-Induced Model of Systemic Sclerosis
Isela Valera¹ and Ram R. Singh², ¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: In bleomycin-induced model of systemic fibrosis and patients with systemic sclerosis, plasmacytoid DC (pDC) are unaffected or reduced systemically (spleen/peripheral blood) but they increase…
Abstract Number: 40 • 2017 ACR/ARHP Annual Meeting
B-Cell Attracting Chemokine-1 (BCA-1) and Macrophage Inflammatory Protein-3 Alpha (MIP-3α) Act Synergistically in the Recruitment of B Cells in the Rheumatoid Synovium
Estefanía Armas-González¹, María Jesús Domínguez-Luis², María Teresa Arce-Franco³, Javier Castro-Hernández³, Vanesa Hernandez⁴, Sagrario Bustabad⁵, Alberto Cantabrana-Alutiz⁶ and Federico Díaz-González⁷, ¹Universidad de La Laguna, Departamento de Medicina Física y Farmacología, Facultad de Medicina, La Laguna, Tenerife, Spain, ²Laboratorio de Reumatología. Hospital Universitario de Canarias, La Laguna, Spain, ³Laboratorio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁴Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, S/C Tenerife, Spain, ⁵Rheumatology, Servicio de Reumatología. Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ⁶Servicio de Reumatología. Hospital Universitario Nuestra Señora de Candelaria, La Laguna, Tenerife, Spain, ⁷Servicio de Reumatología. Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: B cells are recognized as key players in the pathogenesis of rheumatoid arthritis (AR) through the production of autoantibodies, the local production of proinflammatory…
Abstract Number: 397 • 2017 ACR/ARHP Annual Meeting
Anti-Fractalkine Monoclonal Antibody Ameliorates Joint Destruction in Collagen-Induced Arthritis Model through Suppression of Osteoclast Precursor Cell Survival and Migration
Yoshikazu Kuboi¹, Kana Hoshino-Negishi¹, Masayoshi Ohkuro², Wataru Ikeda¹, Tomoya Nakatani¹, Naoto Ishii¹, Toshihiko Yamauchi¹, Nobuyuki Yasuda¹ and Toshio Imai³, ¹KAN Research Institute, Inc., Chuo-ku, Kobe-shi, Japan, ²Research Project Promotion Group, EA Pharma Co., Ltd., Kawasaki-ku, Kawasaki-shi, Japan, ³KAN Research Institute, Inc., Kobe, Japan
Background/Purpose: In the Phase 1/2 clinical study, E6011, a novel humanized anti-fractalkine (FKN) mAb demonstrated a promising efficacy in active RA patients who were inadequately…
Abstract Number: 553 • 2017 ACR/ARHP Annual Meeting
Decreased Circulating CXCR3+CCR9+ Th Cells Coincides with Elevated Levels of Their Ligands CXCL10 and CCL25 in the Salivary Gland of Sjögren’s Syndrome Patients Which Synergistically Facilitate Th Cell Migration
Sofie L.M. Blokland^1,2, Maarten R. Hillen^3,4, Stephan Meller⁵, Bernhard Homey⁵, Glennda Smithson⁶, Aike A. Kruize², Timothy R.D.J. Radstake^2,7 and Joel A.G. van Roon^2,3, ¹Rheumatology & Clinical Immunology/ Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Laboratory of Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Department of Dermatology, University of Düsseldorf, Düsseldorf, Germany, ⁶Takeda Global Research & Development Center, Inc, Chicago, IL, ⁷Rheumatology and Clinical Immunology, Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Primary Sjögren’s syndrome (pSS) is characterized by dryness and lymphocytic infiltration in the salivary glands. CXCR3+ T cells and ligands CXCL9/10/11 are known to…
Abstract Number: 724 • 2017 ACR/ARHP Annual Meeting
Antibodies Against the Chemokine Receptors CXCR3 and CXCR4 Predict Progressive Lung Fibrosis in Systemic Sclerosis (SSc)
Gabriela Riemekasten¹, Elise Siegert² and Harald Heidecke³, ¹Department of Rheumatology, Universitatsklinikum Schleswig-Holstein, Lubeck, Germany, ²Rheumatology and Clinical Immunology, University Hospital Charité, Berlin, Germany, ³CellTrend GmbH Luckenwalde, Luckenwalde, Germany
Background/Purpose: Chemokine receptors CXCR3 and CXCR4 are involved in immune cell migration and in the pathogenesis of inflammatory fibrosis, a key feature of systemic sclerosis…
Abstract Number: 958 • 2017 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-α Induces Production of Eotaxin-1/CCL11 from Fibroblast-like Synoviocyte in Rheumatoid Arthritis
Kuninobu Wakabayashi, Takeo Isozaki, Airi Nishimi, Shinichiro Nishimi, Sho Ishii, Takahiro Tokunaga, Hidekazu Furuya and Tsuyoshi Kasama, Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: Chemokine C-C motif ligand 11 (CCL11) also known as eotaxin-1 is a member of the CC chemokine family, which acts as a major chemoattractant…
Abstract Number: 961 • 2017 ACR/ARHP Annual Meeting
Adalimumab Reduces CXCR4 Expression during Inflammatory Arthritis and in Fibroblast-like Synoviocytes and Osteoclasts Under Chronic TNF Exposure
Bohdan P. Harvey¹, Li Li¹, Mark Konrad¹, Heather Knight¹, Susan Westmoreland², Melanie Ruzek¹ and Zehra Kaymakcalan¹, ¹AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: The CXCL12/CXCR4 chemokine axis has been implicated in the pathogenesis of RA. The expression of this chemokine and receptor has been shown to be…
Abstract Number: 1912 • 2017 ACR/ARHP Annual Meeting
Broad Immunophenotyping Results: CCR10 Expressing CD8 T Cells Distinguish Psoriatic Arthritis from Psoriasis Limited to Skin Involvement
Emmerik F.A. Leijten^1,2, Tessa S. van Kempen^1,2, Michel A.M. Olde Nordkamp^1,2, Fleurieke H. Verhagen^2,3, Sanne Hiddingh^2,3, Jonas J.W. Kuiper^2,3, Marianne L. Boes^2,4 and Timothy R.D.J. Radstake^1,2, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Ophthalmology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴Department of Pediatrics, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Studies that compare the immune cell phenotype or function from patients with psoriatic arthritis (PsA) to patients with psoriasis limited to cutaneous involvement (Pso)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.